High protein levels in the urine, poor kidney function, and high blood pressure at the time of systemic sclerosis (SSc) diagnosis are strong predictors for the future development of scleroderma renal crisis (SRC), a study suggests. These and other laboratory findings…
News
Although serological markers correlate with joint inflammation in patients with systemic sclerosis (SSc), markers that might accurately diagnose systemic sclerosis-rheumatoid arthritis (SSc-RA) overlap syndrome are still lacking, a new study reports. “Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations” was…
A key innate immunity protein called TLR4 is a key driver of organ fibrosis, according to a new study conducted in mice and scleroderma patients. The finding suggests that targeting TLR4 may be an effective therapeutic strategy in certain patients. The study, “TLR4-dependent fibroblast activation…
A protein called BAFF, or B-cell activating factor, was found to drive skin and lung fibrosis in systemic scleroderma (SSc) by altering the balance between two subsets of immune B-cells in a mouse model, indicating its potential as a future therapeutic target, a study reports. Researchers observed that these…
A lower score on the six-minute walk test (6MWT) correlates with disease severity and mortality in patients with systemic sclerosis (SSc), supporting its validity in assessing the prognosis of these patients, a study reports. Results also showed that an additional meter walked during the test corresponded with a…
Malakoplakia, a rare granulomatous disorder, was reported for the first time in a patient with systemic sclerosis in a recent case report. The report, “Bladder Malakoplakia in Systemic Sclerosis Patient: A Case Report and Review Literature,” was published in the Journal of Endourology Case Reports. Systemic sclerosis…
High levels of a protein called KL-6, produced by lung cells and secreted into the blood, can predict early signs of lung function worsening in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD), a study reports. Researchers established a value of 1,273 U/mL for KL-6 as a biomarker for SSc-ILD…
Emerald Health Pharmaceuticals’ lead cannabinoid-derived treatment candidate, EHP-101, has shown potential to prevent skin and lung tissue scaring in a mouse model of systemic sclerosis, the company reports. Emerald also claims that EHP-101’s therapeutic activity is similar or superior to that seen in ajulemic acid, also known as…
News
Variability of Pulmonary Hypertension in SSc Patients Demands Tailored Treatments, Study Argues
Considerable differences in features of pulmonary hypertension among people with systemic sclerosis (SSc) markedly affect their survival chances, and treatment approaches given should be tailored accordingly, according to an analysis of patients grouped according to lung disease severity. SSc patients with pulmonary hypertension (PH) but no evidence — or limited…
Specific traits at the time of diagnosis, including symptoms and lung function status, may predict morbidity and mortality in people with scleroderma, a nine-year follow-up study shows. The age and gender of the patient, type of scleroderma, presence of pulmonary fibrosis or hypertension, and lung function status are among…
Recent Posts
- John Stamos to be honored for longtime support of scleroderma research
- Study maps shift in prescribing patterns as guidelines evolve
- Blood protein may help predict lung decline in scleroderma-related ILD
- Lack of small blood vessel damage patterns may predict milder SSc
- Wireless sensor may help track scleroderma skin changes at home
- New scleroderma survey seeks patient input to guide future research
- Scleroderma added to NIH project targeting autoimmune diseases
- Off-the-shelf cell therapy shows early promise as scleroderma treatment
- Trial to test scleroderma treatments at earliest stages of disease
- Off-label JAK inhibitors may stabilize lung function in systemic sclerosis